WASHINGTON — The Department of Health and Human Services under Secretary Robert F. Kennedy Jr. is weighing a new national push aimed at men who are falling behind on basic health measures, including a possible network of specialized “centers of excellence” tied to hormone care, mental health and chronic disease screening, Dec. 24, 2025.
Men’s health initiative: what HHS is considering and why testosterone is in the middle of it
The emerging men’s health initiative is being discussed as federal officials and clinicians debate how to make evidence-based care easier to access while tightening oversight where marketing and quick-prescribing models may be outpacing medical norms. A recent report described internal conversations at HHS and an FDA meeting where the idea of dedicated centers surfaced alongside calls to revisit how testosterone replacement therapy is regulated and delivered, including through telehealth. Wired reported the discussions.
HHS has not announced a finalized framework, but the direction points to two parallel tracks: expanding services that could look like one-stop clinics for men’s preventive care, and rechecking the guardrails around testosterone prescribing as demand grows. Supporters argue that a men’s health initiative could cut through fragmented care by pairing screening (blood pressure, diabetes, depression, sleep disorders) with standardized follow-up, rather than treating testosterone as a stand-alone fix.
The policy debate arrives after a major federal shift in how testosterone risks are framed. In February 2025, the Food and Drug Administration ordered class-wide labeling changes following its review of the TRAVERSE trial and ambulatory blood pressure monitoring data, adding trial results across products while emphasizing blood pressure warnings where needed. Reuters reported the FDA’s labeling move. That update has sharpened calls for clearer clinical pathways: who should receive testosterone, what monitoring is required, and how to curb inappropriate use.
Telehealth rules are also a live wire. The Drug Enforcement Administration has proposed new pathways for prescribing certain controlled substances via telemedicine, including a special registration approach intended to keep access open while setting conditions for remote prescribing. DEA outlined the proposed telemedicine rules in January 2025. While testosterone itself is not a controlled substance, the same virtual-care ecosystem that accelerated remote prescribing has fueled scrutiny of high-volume, direct-to-consumer medicine — and the men’s health initiative is taking shape inside that broader regulatory reset.
Concerns about marketing-driven “low T” care are not new. A decade ago, major outlets chronicled a fast-growing testosterone marketplace and the anxiety-driven branding that helped it spread. Time documented the rise of “low testosterone” culture in 2014, and Forbes reported in 2013 on the rapid growth of testosterone-focused clinics. Those earlier warning signs now form part of the backdrop for today’s men’s health initiative conversations in Washington.
For patients, the stakes are practical: a new HHS-backed model could standardize testing, require follow-up labs and cardiovascular monitoring, and steer men toward comprehensive evaluation before hormones are prescribed. Whether the “centers of excellence” concept becomes real policy, the administration’s push suggests the men’s health initiative is moving from rhetoric to program design — with testosterone rules likely to be one of the first high-profile tests.
